Test your compound’s capacity to prevent or reduce the burden of metabolic diseases
Obesity, insulin resistance, nonalcoholic fatty liver disease (NAFLD), type 2 diabetes are among the growing group of complex metabolic disorders that representing a major health burden. They all share one feature: mitochondrial dysfunction contributes to their development.
Mitologics’ MitoXpert® platform provides robust assays to investigate the potential of compounds to reduce/prevent mitochondrial alterations in the context of metabolic disorders.
Metabolic syndromes manifest as systemic abnormalities, including hypertension, hyperglycaemia, abdominal fat deposition, dyslipidaemia, and insulin resistance. Their common denominator is impaired OxPHOS function and oxidative stress.
Mitochondrial dysfunction in metabolic diseases is a rapidly emerging area of research and holds great promise for future therapies. Current approaches to the treatment of metabolic disorders aim to maintain mitochondria quantity and morphology, eliminate dysfunctional mitochondria, and reduce oxidative stress.
Our MitoXpert® platform can assess mitochondrial function in various experimental models : mitochondria isolated from rodent organs or cultured cells, in basal or stressed conditions. Our assays allow you to study:
